Houston biotech awarded $4.7MM in homegrown Texas support for new technology to safely improve the treatment of advanced blood cancers and genetic diseases
HOUSTON, May 22, 2023 (GLOBE NEWSWIRE) -- 7 Hills Pharma LLC (“7 Hills” or “7HP”) announced today that it has been awarded $13.5MM in nondilutive grant funds from the Cancer Prevention &...
HOUSTON, Aug. 01, 2022 (GLOBE NEWSWIRE) -- 7 Hills Pharma LLC (“7 Hills” or “7HP”), a clinical-stage pharma company developing a platform of first-in-class oral small molecules to enhance the effectiveness of a wide range of immunotherapies, was awarded a 3-year grant worth almost $3 million from the National Institute of Allergy and Infectious Diseases to progress its work with collaborator Dr. Nisha Garg from the University of Texas Medical Branch (UTMB) toward the creation of the first vaccine against Chagas disease.
HOUSTON, June 09, 2022 (GLOBE NEWSWIRE) -- 7 Hills Pharma LLC (“7 Hills” or “7HP”) has secured newly issued US patent claims that significantly expand the extent of the company’s intellectual...
HOUSTON, May 18, 2022 (GLOBE NEWSWIRE) -- 7 Hills Pharma LLC (“7 Hills” or “7HP”), together with The University of Texas MD Anderson Cancer Center (“MD Anderson”) and Texas Heart Institute (“THI”),...
HOUSTON, March 08, 2022 (GLOBE NEWSWIRE) -- 7 Hills Pharma LLC (“7 Hills” or “7HP”), a clinical-stage drug development company bringing to market a platform of unique, first-in-class oral small...
HOUSTON, Nov. 01, 2021 (GLOBE NEWSWIRE) -- 7 Hills Pharma LLC (“7 Hills” or “7HP”), a clinical-stage drug development company bringing to market a platform of unique, first-in-concept oral small molecules to augment immunotherapies for solid tumor cancers as well as infectious disease vaccinations, today announced that it has successfully completed its Phase I clinical trial to evaluate 7HP349, their lead molecule. 7HP349 is the firstclinical candidate to emerge from 7HP’s proprietary and differentiated platform of allosteric integrin agonists. The study was supported by a $2 million Small Business Innovation Research grant from the U.S. National Cancer Institute.
HOUSTON, Nov. 09, 2020 (GLOBE NEWSWIRE) -- 7 Hills Pharma, a clinical stage immunotherapy company focused on the development of drugs for treatment and prevention of cancer and infectious diseases, announced today the first healthy volunteers have been dosed in a Phase 1 trial of 7HP349, the company’s first-in-concept immunostimulant to improve the effectiveness of immunotherapies.
HOUSTON, Aug. 04, 2020 (GLOBE NEWSWIRE) -- 7 Hills Pharma, a clinical-stage immunotherapy company focused on the development of drugs for treatment and prevention of cancer and infectious diseases, announced today it had received broad patent protection from the U.S. Patent and Trademark Office (USPTO) on four patents covering the use of the company’s integrin activators with any therapeutic antibody, any checkpoint inhibitor for immuno-oncology, and any vaccine.
HOUSTON, July 07, 2020 (GLOBE NEWSWIRE) -- 7 Hills Pharma, a clinical stage immunotherapy company focused on the development of drugs for treatment and prevention of cancer and infectious diseases, announced today that preclinical studies reveal 7HP349, an oral integrin activator that promotes cell adhesion, significantly increases IgG binding antibodies with a vaccine targeting SARS-CoV-2 (COV2), the virus that causes COVID-19.